Background:

Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.

Poloxime (100 μM) inhibits phosphopeptide binding to polo-box domain (PBD) of polo-like kinase 1 (Plk1)[2].

参考文献:
[1]. Liu M, et al. Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors. Bioorg Med Chem Lett. 2015 Feb 1;25(3):431-4.
[2]. Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol. 2013 Feb 15;8(2):303-8.